(Sharecast News) - Merck & Co beat market forecasts with its first-quarter results on Thursday and raised its full-year guidance on the back of strong growth for Keytruda, its flagship humanised monoclonal antibody (PD-1 inhibitor) used to treat 18 types of cancer.
Group revenues rose 5% to $16.29bn, well ahead of...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE